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論 文 内 容 の 要 旨 
[目的] 
 Alzheimer disease (AD) is characterized by progressive cognitive decline caused by synaptic dysfunction and 
neurodegeneration in the brain, and late-onset AD (LOAD), genetically classified as a polygenetic disease, is the 
major form of dementia in the elderly.  It was shown thatβamyloid, deposited in the AD brain, interacts with 
dynamin 1, and the dynamin 2 (DNM2) gene homologous to the dynamin 1 gene is encoded at chromosome 
19p13.2 where a susceptibility locus was detected by linkage analysis.  To test the genetic association of LOAD 
with the DNM2 gene, we performed a case-control study of patients with LOAD and control subjects in a 
Japanese population. 
[方法] 
 The 429 (69.9% female) LOAD patients, composed of 66 with definite and 363 with probable AD ; mean±S.D. 
age at onset was 72.3±8.1 range 60－94 years ; and age at blood drawing was 77.4±8.7, range 60－98 years.  
Controls consisted of non-demented elderly subjects were composed of 438 individuals (63.7% female) ; age at 
assessment was 74.5±5.5, range 60－99 years.  Hippocampal tissue was also obtained from the postmortem 
brains of 22 patients with AD (age : 82.8±85 years, 63.6% female) and 12 controls (age : 89.0±7.0 years, age at 
onset : 72.9±7.2 years, 58.0% female).  DNA was extracted from peripheral blood using a QIAamp DNA Blood 
Kit (Qiagen, Tokyo, Japan), and from brain tissue by phenol-chloroform method.  Genotyping was performed by 
a quantitative genotyping method using the TaqMan SNP Genotyping System (Applied Biosystems).  The 
genotype of the APOE gene was determined by a PCR-RFLP method (Wenham et a1. 1991).  Total RNA was 
isolated from frozen hippocampal tissues using the acid guanidine-phenol-chloroform RNA extraction method 
provided as ISOGEN (Nippon Gene, Toyama, Japan), and purified using an RNeasy Mini kit (Qiagen). 
[成績] 
 Four hundred and twenty nine cases and 438 sex- and age-matched controls were genotyped, and their 
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genotype distributions were in Hardy-Weinberg equilibrium both in cases and controls.  In this data set, the 
APOE-ε4 is associated with LOAD (p＜1x10－10), and odds ratio carrying one APOE-ε4 was 4.3 (95% C.I.＝
3.12-6.16) and that carrying two APOE-ε4 was 28.4 (95% C.I.＝6.75－119) compared to non-APOE-ε4 carriers.  
LD statistics indicated more than three haplotype blocks in the DNM2 gene region.  No validated SNPs were 
available between rs873016 and rs1109376 at the distance of 20 kb approximately, and no strong evidence of LD 
was found between these two SNPs.  The case control study showed that P values less than 0.05 were found in 4 
SNPs located from intron 6 to 3’ UTR for allele distribution, and in 7 SNPs from intron 1 to 3’ UTR for genotype 
frequencies ; their odds ratios were between 1.56 and 1.75.  Calculation with SNPSpD indicated that the 
effective number of independent marker loci was 8.3094, and the experiment-wide significance threshold was 
0.006.  Therefore, rs3760781 remained significant after correction for multiple testing (p＝0.003).  To examine 
the interaction between the DNM2 gene and, APOE gene, the cases and controls were divided into APOE-ε4 
carriers and non-APOE-ε4 carriers.  In non-APOE-ε4 carriers, 7 markers showed P values less than 0.05, and 
the experiment-wide significance threshold (0.0059) supported a significant association at rs892086 (p＝0.003) 
as well as at rs3760781 (p＝0.004).  However, no association was found in APOE-ε4 carriers, indicating that 
the association of the DNM2 gene is specific for non-APOE-ε4 carriers in our dataset.  To examine the 
expression of the DNM2 gene in the AD hippocampual tissue, we measured the amount of DNM2 cDNA 
normalized to that of β actin cDNA using quantitative PCR.  Ten LOAD and 8 control subjects showed that 
the amount of DNM2 mRNA in AD hippocampal tissue was significantly lower compared to that in controls (p＜
0.01). 
[総括] 
 We found a significant association of late-onset AD with SNP markers of the DNM2 gene, especially in 
non-carriers of the apolipoprotein E-ε4 allele.  Even though subjects with the genotype homozygous for a risk 
allele of rs3760781 showed no mutation in exons of the DNM2 gene, expression of DNM2 mRNA in the 
hippocampus was decreased in the patients compared to non-demented controls.  We propose herein that the 
DNM2 gene is a novel susceptibility gene for late-onset AD. 
論 文 審 査 の 結 果 の 要 旨 
 アルツハイマー病（AD）は脳神経細胞の変性・消滅をともなう進行性認知症であり、高齢発症アルツハイマー病
（LOAD）において原因は多遺伝子によると考えられている。変性の原因であるベータアミロイドはダイナミン１
（DNM1）遺伝子の機能障害に関与し、DNM1 遺伝子が AD に障害しやすい遺伝子として知られていた。その DNM1
遺伝子に同様の機能を有する DNM2 遺伝子は未だに AD との関係で報告がない。本研究は日本の LOAD 患者におい
て DNM2 との相関を検討した。この case control study では LOAD 患者 429 名に性別・年齢をマッチした高齢健常
群 438 名を用いた。さらに AD と確定した 22 名の海馬を postmortem study に使用した。その結果 12SNP の内に７
つが優位に相関した（p＜0.006）。LOAD 患者を APOE-4 を有するとしない２群に分けて統計をおこなうと APOE-4
を有する群で相関がみられず、APOE-4 有しない群では 12SNP のうちに７つで優位な相関（p＜0.0059）がみられた。
LOAD 患者で海馬の DNM2 の mRNA の発現がコントロールより減少した。この研究ではじめて DNM2 遺伝子と
LOAD の関係は明らかになった。日本人において APOE-4 を有しない者はこの遺伝子が LOAD に新規リスク遺伝子
であることが明らかになり、学位の授与に値すると考えられる。 
